Skip to main content
OpenTrials
Completed

NCT Number: NCT00749463

Evaluation of the Safety Profile, Quit and Reduction Rate After Nicorette® Gum and Patch Treatment

To evaluate the safety, smoking cessation and reduction rate during 3 months of active nicotine replacement therapy (NRT) and a follow-up period of 3 months in smoking hospital physicians and staff who are motivated to quit

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Beijing ChaoYang Hospital, Beijing, Beijing Municipality, China

Loading trial locations.

About this study

Using Nicorette® gum 2 mg, 4 mg and Nicorette® patch 5 mg/16 h, 10 mg/16 h, 15 mg/16 h to alleviate nicotine cravings and withdrawal symptoms and assist smoking cessation in smoking hospital physicians and staff who are motivated to quit. During the study, brief telephone consultation and SMS are provided as behavioral supports.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy males and females, aged 18 years or older
  • Normal dental status and chewing ability for nicotine gum users; normal skin without excessive hair growth on tested areas for nicotine patch users
  • Current daily smoker for at least two years
  • Have a carbon monoxide (CO) level of at least 10 parts per million (ppm) after at least 15 smoke-free minutes
  • Be motivated to stop smoking with the help of nicotine gum or patch treatment.
  • Evidence of a personally signed and dated informed consent form indicating that the subject has been informed of all pertinent aspects of the trial
  • Be willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.

Exclusion criteria

  • Current use of other tobacco-containing products e.g. snuff, chewing tobacco, cigars, or pipes.
  • Use of any other stop-smoking products (nicotine or non-nicotine) or treatment (hypnosis, acupuncture, etc) during the study i.e. during the last 6-month period.
  • Unstable angina pectoris or myocardial infarction during the previous 3 months.
  • Pregnancy, lactation or intended pregnancy.
  • Any major metabolic disease, clinically important renal, hepatic disease.
  • Suspected alcohol or drug abuse.
  • Participation in other clinical trials in the previous three months, or during study participation.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or investigational product administration or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the subject inappropriate for entry into this trial.

Treatment and study plan

Nicotine gum

Drug

2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks

Other names: Nicorette® Gum

Nicotine patch

Drug

Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.

Other names: Nicorette® Patch

Primary outcomes

  1. Treatment-Related Adverse Events

    Time frame: 24 Weeks

    Percentage of subjects with treatment-related adverse events by preferred term, included if the percentage in any single arm was 1% or higher

  2. Self-Reported Smoking Reduction

    Time frame: 24 Weeks

    Percentage of subjects self-reporting reduction from baseline in number of cigarettes smoked per day

  3. Smoking Abstinence

    Time frame: 24 Weeks

    Continuous carbon monoxide (CO)-verified Smoking Abstinence from Quit day

Secondary outcomes

  1. Carbon Monoxide (CO)-Verified Smoking Reduction

    Time frame: Baseline to Week 24

    Percentage of participants with carbon monoxide (CO)-verified reduction from baseline in number of cigarettes smoked per day (%)

  2. Smoking Consumption Per Day

    Time frame: 24 Weeks from last visit:

    Number of cigarettes smoked by subjects reporting smoking since last visit - total during the day (for daily smokers)

  3. Smoking Consumption Per Week

    Time frame: 24 Weeks from last visit:

    Number of cigarettes smoked by subjects reporting smoking since last visit - total during the the week (for non-daily smokers)

  4. Point Prevalence Smoking Abstinence (PPSA)

    Time frame: 24 Weeks

    Point Prevalence Smoking Abstinence since last visit. Point prevalence abstinence is defined as the percentage of former smokers who are not smoking at a particular point in time, typically at the time of assessment.

Sponsors and collaborators

Lead sponsor

McNeil AB

Industry

Registry information

Important dates

Study start
2009
Primary completion
2009
Study completion
2009
First posted
Sep 9, 2008
Registry last updated
Jul 13, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.